Over the last decade, monoclonal antibodies targeting programmed cell death protein 1 (PD-1, also known as PDCD1 and CD279) or programmed cell death ligand 1 (PD-L1, also known as CD274 and B7-H1) to restore tumor-induced immune deficiency have emerged as a promising treatment. Here, PDCD1 is linked to Immunodeficiency.